{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T22:40:49Z","timestamp":1718232049970},"reference-count":81,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.arteri.2015.10.006","type":"journal-article","created":{"date-parts":[[2015,12,4]],"date-time":"2015-12-04T18:07:55Z","timestamp":1449252475000},"page":"19-30","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Una visi\u00f3n actualizada del tratamiento hipolipemiante de alta intensidad en los pacientes de alto riesgo cardiovascular"],"prefix":"10.1016","volume":"28","author":[{"given":"Juan","family":"Pedro-Botet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Pint\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2015.10.006_bib0410","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2015.10.006_bib0415","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA."},{"key":"10.1016\/j.arteri.2015.10.006_bib0420","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2015.10.006_bib0425","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet."},{"key":"10.1016\/j.arteri.2015.10.006_bib0430","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4 S)","volume":"344","year":"1994","journal-title":"Lancet."},{"key":"10.1016\/j.arteri.2015.10.006_bib0435","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2015.10.006_bib0440","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","volume":"339","year":"1998","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2015.10.006_bib0445","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA."},{"key":"10.1016\/j.arteri.2015.10.006_bib0450","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet."},{"key":"10.1016\/j.arteri.2015.10.006_bib0455","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet."},{"key":"10.1016\/j.arteri.2015.10.006_bib0460","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2015.10.006_bib0465","doi-asserted-by":"crossref","DOI":"10.1177\/2047487315569401","article-title":"EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries","author":"Kotseva","year":"2015","journal-title":"Eur J Prev Cardiol."},{"key":"10.1016\/j.arteri.2015.10.006_bib0470","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.arteri.2013.07.006","article-title":"Consecuci\u00f3n del objetivo terap\u00e9utico del colesterol de las lipoprote\u00ednas de baja densidad en las unidades de l\u00edpidos y riesgo vascular de la Sociedad Espa\u00f1ola de Arteriosclerosis","volume":"25","author":"Pedro-Botet","year":"2013","journal-title":"Clin Investig Arterioscler."},{"key":"10.1016\/j.arteri.2015.10.006_bib0475","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.recesp.2011.05.022","article-title":"Magnitud y caracter\u00edsticas del riesgo residual lip\u00eddico en pacientes con antecedentes de revascularizaci\u00f3n coronaria: estudio ICP-Bypass","volume":"64","author":"Gonz\u00e1lez-Juanatey","year":"2011","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.arteri.2015.10.006_bib0480","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.recesp.2010.10.030","article-title":"Prevalencia y caracter\u00edsticas de la dislipemia en pacientes en prevenci\u00f3n primaria y secundaria tratados con estatinas en Espa\u00f1a. Estudio DYSIS-Espa\u00f1a","volume":"64","author":"Gonz\u00e1lez-Juanatey","year":"2011","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.arteri.2015.10.006_bib0485","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.recesp.2013.04.012","article-title":"Cifras de colesterol adecuadas en pacientes coronarios y diab\u00e9ticos. An\u00e1lisis seg\u00fan especialidades m\u00e9dicas y comunidades aut\u00f3nomas","volume":"66","author":"P\u00e9rez de Isla","year":"2013","journal-title":"Rev Esp Cardiol."},{"issue":"Supl.2","key":"10.1016\/j.arteri.2015.10.006_bib0490","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.recesp.2012.07.005","article-title":"Un problema alarmante en prevenci\u00f3n secundaria: bajo cumplimiento (estilo de vida) y baja adherencia (farmacol\u00f3gica)","volume":"65","author":"Fuster","year":"2012","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.arteri.2015.10.006_bib0495","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.arteri.2015.10.006_bib0500","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA."},{"key":"10.1016\/j.arteri.2015.10.006_bib0505","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2015.10.006_bib0510","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2013.02.027","article-title":"Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70mg\/dl or \u2265 50% reduction in high-risk patients: results from VOYAGER","volume":"228","author":"Karlson","year":"2013","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.arteri.2015.10.006_bib0515","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.atherosclerosis.2015.05.029","article-title":"To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology\/American Heart Association guidelines? A VOYAGER meta-analysis","volume":"241","author":"Karlson","year":"2015","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.arteri.2015.10.006_bib0520","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.numecd.2012.03.003","article-title":"Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: results from VOYAGER","volume":"22","author":"Karlson","year":"2012","journal-title":"Nutr Metab Cardiovasc Dis."},{"key":"10.1016\/j.arteri.2015.10.006_bib0525","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1476-511X-12-9","article-title":"Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe","volume":"12","author":"Yamazaki","year":"2013","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.arteri.2015.10.006_bib0530","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.arteri.2015.02.004","article-title":"Actualizaci\u00f3n de las tablas de planificaci\u00f3n terap\u00e9utica hipocolesterolemiante orientada a la obtenci\u00f3n de los objetivos","volume":"27","author":"Masana","year":"2015","journal-title":"Clin Investig Arterioscler."},{"key":"10.1016\/j.arteri.2015.10.006_bib0535","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.recesp.2014.05.008","volume":"67","author":"Lobos Bejarano","year":"2014","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.arteri.2015.10.006_bib0540","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/eurheartj\/ehq370","article-title":"Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk \u2265 5% or Framingham risk>20%: post hoc analyses of the JUPITER trial requested by European health authorities","volume":"32","author":"Koenig","year":"2011","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2015.10.006_bib0545","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized trial","volume":"285","author":"Schwart","year":"2001","journal-title":"JAMA."},{"key":"10.1016\/j.arteri.2015.10.006_bib0550","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2015.10.006_bib0555","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"De Lemos","year":"2004","journal-title":"JAMA."},{"key":"10.1016\/j.arteri.2015.10.006_bib0560","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/CIRCULATIONAHA.106.654756","article-title":"Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE)","volume":"115","author":"Deedwania","year":"2007","journal-title":"Circulation."},{"key":"10.1016\/j.arteri.2015.10.006_bib0565","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2015.10.006_bib0570","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA."},{"key":"10.1016\/j.arteri.2015.10.006_bib0575","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","article-title":"Intensive lowering of LDL cholesterol with 80mg versus 20mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial","volume":"376","author":"Armitage","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2015.10.006_bib0580","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJMp1106689","article-title":"Weighing the benefits of high-dose simvastatin against the risk of myopathy","volume":"365","author":"Egan","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2015.10.006_bib0585","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.amjcard.2011.09.019","article-title":"Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia","volume":"109","author":"Kawashiri","year":"2012","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.arteri.2015.10.006_bib0590","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.atherosclerosis.2013.10.022","article-title":"Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20mg plus ezetimibe 10mg vs. simvastatin 40 or 80mg plus ezetimibe 10mg in high-risk patients: Results of the GRAVITY randomized study","volume":"232","author":"Ballantyne","year":"2014","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.arteri.2015.10.006_bib0595","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2015.10.006_bib0600","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.atherosclerosis.2015.03.002","article-title":"SAhould the high-intensity colesterol-lowering therapy strategy replace he high-intensity statin therapy?","volume":"240","author":"Masana","year":"2015","journal-title":"Atherosclerosis."},{"issue":"Suppl","key":"10.1016\/j.arteri.2015.10.006_bib0605","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.arteri.2015.10.006_bib0610","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.cjca.2013.09.023","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus Update","volume":"29","author":"Mancini","year":"2013","journal-title":"Can J Cardiol."},{"key":"10.1016\/j.arteri.2015.10.006_bib0615","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/clpt.2014.84","article-title":"A current approach to statin intolerance","volume":"96","author":"Tompkins","year":"2014","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.arteri.2015.10.006_bib0620","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA."},{"key":"10.1016\/j.arteri.2015.10.006_bib0625","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/acr.21671","article-title":"Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase associated autoimmune myopathy","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.arteri.2015.10.006_bib0630","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation."},{"key":"10.1016\/j.arteri.2015.10.006_bib0635","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3949\/ccjm.78a.10073","article-title":"Statin myopathy: a common dilemma not reflected in clinical trials","volume":"78","author":"Fernandez","year":"2011","journal-title":"Cleve Clin J Med."},{"key":"10.1016\/j.arteri.2015.10.006_bib0640","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"Lancet."},{"key":"10.1016\/j.arteri.2015.10.006_bib0645","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1253\/circj.CJ-11-1385","article-title":"Effects of rosuvastatin and atorvastatin on renal function: meta-analysis","volume":"76","author":"Wu","year":"2012","journal-title":"Circ J."},{"key":"10.1016\/j.arteri.2015.10.006_bib0650","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1016\/j.ijcard.2012.05.010","article-title":"Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis","volume":"167","author":"Savarese","year":"2013","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.arteri.2015.10.006_bib0655","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.atherosclerosis.2011.12.011","article-title":"Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program","volume":"221","author":"Stein","year":"2012","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.arteri.2015.10.006_bib0660","doi-asserted-by":"crossref","first-page":"251","DOI":"10.7326\/0003-4819-157-4-201208210-00005","article-title":"Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis","volume":"157","author":"Upadhyay","year":"2012","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.arteri.2015.10.006_bib0665","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-157-4-201208210-00007","article-title":"Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis","volume":"157","author":"Palmer","year":"2012","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.arteri.2015.10.006_bib0670","unstructured":"AstraZeneca Pharmaceuticals. Crestor (rosuvastatin calcium)[package insert] Wilmington (DE): AstraZeneca Pharmaceuticals; 2007."},{"key":"10.1016\/j.arteri.2015.10.006_bib0675","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2217\/clp.13.5","article-title":"Increased frequency of microalbuminuria in patients receiving statins","volume":"8","author":"Robles","year":"2013","journal-title":"Clin Lipidol."},{"key":"10.1016\/j.arteri.2015.10.006_bib0680","doi-asserted-by":"crossref","first-page":"e31639","DOI":"10.1371\/journal.pone.0031639","article-title":"Statin use and the presence of microalbuminuria. Results from the ERICABEL trial: a non-interventional epidemiological cohort study","volume":"7","author":"Van der Tol","year":"2012","journal-title":"PLoS One."},{"key":"10.1016\/j.arteri.2015.10.006_bib0685","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2015.10.006_bib0690","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.regg.2012.05.005","article-title":"Statins, diabetes risk and the treatment of hypercholesterolemia in elderly people","volume":"47","author":"Pint\u00f3","year":"2012","journal-title":"Rev Esp Geriatr Gerontol"},{"key":"10.1016\/j.arteri.2015.10.006_bib0695","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a metaanalysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA."},{"key":"10.1016\/j.arteri.2015.10.006_bib0700","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1464-5491.2011.03553.x","article-title":"Effects of rosuvastatin and atorvastatin on glycaemic control in type 2 diabetes-the CORALL study","volume":"29","author":"Simsek","year":"2012","journal-title":"Diabet Med."},{"key":"10.1016\/j.arteri.2015.10.006_bib0705","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/j.1365-2125.2012.04403.x","article-title":"Statins and risk of treated incident diabetes in a primary care population","volume":"75","author":"Zaharan","year":"2013","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.arteri.2015.10.006_bib0710","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.atherosclerosis.2015.06.001","article-title":"Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes","volume":"241","author":"Vallejo-Vaz","year":"2015","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.arteri.2015.10.006_bib0715","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.mayocp.2013.07.013","article-title":"Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects","volume":"88","author":"Swiger","year":"2013","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.arteri.2015.10.006_bib0720","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/pds.2308","article-title":"Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population","volume":"21","author":"Bakhai","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.arteri.2015.10.006_bib0725","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jacl.2014.02.010","article-title":"A clinician's guide to statin drug-drug interactions","volume":"8","author":"Kellick","year":"2014","journal-title":"J Clin Lipidol."},{"key":"10.1016\/j.arteri.2015.10.006_bib0730","unstructured":"FDA US Food and Drug Administration. FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin)to reduce the risk of muscle injury [consultado 26 Jul 2015]. Disponible en: ttp:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm256581.htm)."},{"key":"10.1016\/j.arteri.2015.10.006_bib0735","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2147\/VHRM.S5551","article-title":"Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals","volume":"5","author":"Saito","year":"2009","journal-title":"Vasc Health Risk Manag."},{"key":"10.1016\/j.arteri.2015.10.006_bib0740","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1177\/0091270008319794","article-title":"Same drug, different dosing: differences in dosing for drugs approved in the United States, Europe, and Japan","volume":"48","author":"Malinowski","year":"2008","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.arteri.2015.10.006_bib0745","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.79","volume":"86","author":"Kesitalo","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.arteri.2015.10.006_bib0750","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ahj.2013.01.025","article-title":"Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy","volume":"165","author":"Danik","year":"2013","journal-title":"Am Heart J."},{"key":"10.1016\/j.arteri.2015.10.006_bib0755","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.medcli.2013.07.030","article-title":"Riesgo de interacciones farmacol\u00f3gicas por la coadministraci\u00f3nde estatinas con f\u00e1rmacos metabolizados por la isoenzima 3A4 del citocromo P450: estudio epidemiol\u00f3gico, transversal y multic\u00e9ntrico","volume":"143","author":"Mostaza","year":"2014","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.arteri.2015.10.006_bib0760","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1517\/14712598.2012.748743","article-title":"Anti-PCSK9 therapies for the treatment of hypercholesterolemia","volume":"13","author":"Hooper","year":"2013","journal-title":"Expert Opin Biol Ther."},{"key":"10.1016\/j.arteri.2015.10.006_bib0765","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0140-6736(14)61009-6","article-title":"LDL cholesterol: controversies and future therapeutic directions","volume":"384","author":"Ridker","year":"2014","journal-title":"Lancet."},{"key":"10.1016\/j.arteri.2015.10.006_bib0770","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3909\/ricm0741","article-title":"Management of hypercholesterolemia for prevention of atherosclerotic cardiovascular disease: focus on the potential role of recombinant anti-PCSK9 monoclonal antibodies","volume":"15","author":"Verma","year":"2014","journal-title":"Rev Cardiovasc Med."},{"key":"10.1016\/j.arteri.2015.10.006_bib0775","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet."},{"key":"10.1016\/j.arteri.2015.10.006_bib0780","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation."},{"key":"10.1016\/j.arteri.2015.10.006_bib0785","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.arteri.2015.10.006_bib0790","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE\u2013TIMI 57): a randomised, placebo-controlled, dose ranging phase 2 study","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet."},{"key":"10.1016\/j.arteri.2015.10.006_bib0795","doi-asserted-by":"crossref","unstructured":"Koren MJ, Stein E, Roth EM. Efficacy, safety and tolerability of alirocumab 150mg Q2W, a full human PCSK9 monoclonal antibody: a pooled analysis of 352 patients from Phase 2. Presented at: National Lipid Association Scientific Session, Las Vegas, NV, USA, 30 May\u20132 June 2013.","DOI":"10.1016\/j.jacl.2013.03.085"},{"key":"10.1016\/j.arteri.2015.10.006_bib0800","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/CIRCULATIONAHA.113.001969","volume":"128","author":"Desai","year":"2013","journal-title":"Circulation."},{"key":"10.1016\/j.arteri.2015.10.006_bib0805","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2015.10.006_bib0810","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Open-label study of long-term evaluation against LDL cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med."}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916815001564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916815001564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T21:32:50Z","timestamp":1718227970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916815001564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0214916815001564"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2015.10.006","relation":{},"ISSN":["0214-9168"],"issn-type":[{"value":"0214-9168","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Una visi\u00f3n actualizada del tratamiento hipolipemiante de alta intensidad en los pacientes de alto riesgo cardiovascular","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2015.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Sociedad Espa\u00f1ola de Arteriosclerosis. Published by Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}